Lakewood-Amedex Receives Notice of Allowance for Two U.S. Patents Covering the Broad-Spectrum Antimicrobial Nu-8 Bisphosphocin®
The "Notice of Allowance" indicates that the USPTO is satisfied that the patent applications meet all USPTO requirements.
- The "Notice of Allowance" indicates that the USPTO is satisfied that the patent applications meet all USPTO requirements.
- Steve Parkinson, President and CEO of Lakewood-Amedex, commented, "Allowance of the broad Nu-8 compound patent application is an important development for us.
- An earlier animal model demonstrated that a single one-hour inhaled Bisphosphocin treatment was enough to eradicate a severe Pseudomonas aeruginosa lung infection.
- The Company's products and technology are covered by an extensive patent portfolio consisting of granted and/or issued patents and pending patent applications covering many major pharmaceutical markets.